Inlay

1 week to start🔥 New @focalplane.bsky.social webinar series focused on #CellMigration, register & join us▶️, it will be fun! pls spread the word, in the next one, ECRs could apply to show their work ;) ▶️ to register: focalplane.biologists.com/2026/05/29/n... @dgz.bsky.social @the-node.bsky.social

Saishree S. Iyer and Anna Akhmanova @utrechtuniversity.bsky.social review the mechanisms controlling plus-end elongation of centriolar and ciliary #microtubules, revealing shared principles. rupress.org/jcb/article/... #Centrioles #Cilia #Cytoskeleton

Colchicine, disrupting microtubules & inhibiting NLRP3 inflammasome, shows promise in treating atherosclerosis in recent studies. PMID:42045490, Nat Cardiovasc Res 2026 https://doi.org/10.1038/s44161-026-00807-5 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪

A day in the life of a growing hiPSC spheroid expressing endogenously mStayGold-tagged histone 3.3 for #FluorescenceFriday and the #Snouty aficionados. 28 hours (and >50,000 exposures) later and they are still going! Home-brewed volume projection.

Over the past decade, colchicine has re-emerged as a promising therapeutic candidate for atherosclerotic cardiovascular disease. Here we review evidence from large randomized controlled trials together with advances in mechanistic research that have clarified how colchicine modulates vascular inflammation and plaque stability. Canonically, colchicine disrupts microtubule dynamics and suppresses NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation. Beyond these actions, it limits oxidative stress, modulates cytoskeletal cross-talk, attenuates cholesterol crystal formation and reprograms inflammatory and metabolic proteomic networks. Colchicine influences multiple vascular and immune cell types, including neutrophils, monocytes, macrophages, endothelial cells, smooth muscle cells and platelets, collectively reducing vascular inflammation and promoting plaque stability. Notably, while colchicine has demonstrated benefit in coronary artery disease, several rec

How is NGFR expression linked to melanoma aggressiveness? Laura Nogués, Héctor Peinado @hps2022.bsky.social et al identify non-muscle myosin II as downstream NGFR target mediating invasiveness and immunotherapy resistance link.springer.com/article/10.1...

Our June issue is here! rupress.org/jcb/issue/22... The cover shows a maximum intensity projection from a confocal image stack showing an angiogenic sprout emerging from an engineered microvessel. From @lakynm.bsky.social et al. of the Matthew Kutys lab: rupress.org/jcb/article/... #Cytoskeleton

Immunotherapy has reshaped melanoma treatment, yet the majority of patients fail to respond or develop resistance. Nerve growth factor receptor (NGFR/p75NTR/CD271) has been linked to melanoma aggressi...

Tell me a funding scheme is not ‘fit for purpose’ without telling me a funding scheme is not ‘fit for purpose’…. If Science careers were unstable in the older systems - then this is non functional

Voting is now open in our image competition with #ELMI2026. Thanks to everyone that entered the competition, we received so many wonderful entries. Voting closes on 18 June, the penultimate day of #ELMI2026 @ppbioimaging.bsky.social. focalplane.biologists.com/2026/06/08/f...

Discovery Projects (DP27) still won’t be announced until mid–late Jan. 2027, i.e. 13 months after EOI submission! Similarly, Laureate F’ships – 11 months. However, gladly, Future Fellowships (FT26) will 9 months (back to “normal”).